Novo Nordisk A/S (NYSE:NVO) – Research analysts at Jefferies Group issued their Q3 2016 EPS estimates for shares of Novo Nordisk A/S in a note issued to investors on Thursday. Jefferies Group analyst J. Holford anticipates that the brokerage will post earnings of $0.58 per share for the quarter. Jefferies Group has a “Hold” rating on the stock. Jefferies Group also issued estimates for Novo Nordisk A/S’s FY2016 earnings at $2.25 EPS, FY2017 earnings at $2.55 EPS, FY2018 earnings at $2.74 EPS, FY2019 earnings at $2.93 EPS and FY2020 earnings at $3.29 EPS.
A number of other analysts have also recently issued reports on NVO. Bank of America Corp. set a $57.00 target price on Novo Nordisk A/S and gave the company a “hold” rating in a research report on Saturday, September 17th. Zacks Investment Research cut Novo Nordisk A/S from a “hold” rating to a “sell” rating in a research report on Monday, July 4th. HSBC reissued a “hold” rating on shares of Novo Nordisk A/S in a research report on Thursday. Pacific Crest raised Novo Nordisk A/S from a “neutral” rating to an “outperform” rating in a research report on Tuesday, September 13th. Finally, Citigroup Inc. reissued a “buy” rating on shares of Novo Nordisk A/S in a research report on Wednesday, August 3rd. Seven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $61.33.
Novo Nordisk A/S (NYSE:NVO) traded up 0.0648% during mid-day trading on Friday, reaching $39.6957. The company’s stock had a trading volume of 1,985,663 shares. The firm’s 50 day moving average price is $44.21 and its 200 day moving average price is $51.52. The stock has a market cap of $100.68 billion, a price-to-earnings ratio of 18.7687 and a beta of 0.73. Novo Nordisk A/S has a 12-month low of $39.03 and a 12-month high of $59.00.
Hedge funds have recently bought and sold shares of the stock. BlackRock Institutional Trust Company N.A. acquired a new stake in Novo Nordisk A/S during the first quarter valued at approximately $549,000. Bessemer Group Inc. boosted its stake in Novo Nordisk A/S by 0.8% in the first quarter. Bessemer Group Inc. now owns 35,112 shares of the company’s stock valued at $1,903,000 after buying an additional 288 shares in the last quarter. Carnick & Kubik LLC boosted its stake in Novo Nordisk A/S by 1.7% in the first quarter. Carnick & Kubik LLC now owns 27,994 shares of the company’s stock valued at $1,517,000 after buying an additional 460 shares in the last quarter. Folketrygdfondet boosted its stake in Novo Nordisk A/S by 5.9% in the first quarter. Folketrygdfondet now owns 7,352,675 shares of the company’s stock valued at $398,441,000 after buying an additional 407,387 shares in the last quarter. Finally, Canada Pension Plan Investment Board acquired a new stake in Novo Nordisk A/S during the first quarter valued at approximately $26,380,000. 7.54% of the stock is owned by institutional investors and hedge funds.
About Novo Nordisk A/S
Novo Nordisk A/S is a healthcare company. The Company is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company’s business segments include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1), other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity.
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.